

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/4179955/publications.pdf](https://exaly.com/author-pdf/4179955/publications.pdf)

Version: 2024-02-01

365
papers

50,657
citations

1256

107
h-index

1277

219
g-index

384
all docs

384
docs citations

384
times ranked

22300
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis. <i>Journal of Hepatology</i> , 2023, 79, 910-923.	4.0	3
2	Prospective direct comparison of noninvasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 58, 888-902.	3.8	2
3	Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection. <i>Gastro Hep Advances</i> , 2022, 1, 393-402.	0.7	4
4	Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. <i>Biomedicines</i> , 2022, 10, 699.	3.3	10
5	Possible Conflict of Interest statement :. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	4.8	2
6	External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B. <i>Gastro Hep Advances</i> , 2022, 1, 604-617.	0.7	2
7	External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. <i>JHEP Reports</i> , 2021, 3, 100298.	5.6	6
8	Prospective external validation of a new noninvasive test for the diagnosis of nonalcoholic steatohepatitis in patients with type 2 diabetes. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 952-966.	3.8	8
9	Baveno VI criteria as a prognostic factor for clinical complications in patients with compensated cirrhosis. <i>Digestive and Liver Disease</i> , 2021, , .	1.0	2
10	Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 72, 828-838.	4.0	60
11	Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 998-1007.	1.6	9
12	Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2702.	2.6	26
13	Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. <i>Journal of Hepatology</i> , 2020, 73, 1046-1062.	4.0	93
14	Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 681-691.	1.6	8
15	Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus. <i>World Journal of Hepatology</i> , 2020, 12, 1326-1340.	2.1	2
16	Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 518-526.	4.8	70
17	PS-191-External validation of an algorithm combining multi-analyte blood tests (FibroTest-LCR1-LCR2) for identifying subjects at risk of hepatocellular carcinoma among patients with chronic liver disease. <i>Journal of Hepatology</i> , 2019, 70, e118.	4.0	0
18	THU-484-Mass spectrometric analysis of serum haptoglobin fucosylation in patients stratified according to fibrosis stages, and the presence of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, e374.	4.0	0

#	ARTICLE	IF	CITATIONS
19	External validation of an algorithm combining multi-analyte blood tests (FibroTest-LCR1&LCR2) to identify subjects at risk of hepatocellular carcinoma in patients with chronic liver disease. <i>GastroHep</i> , 2019, 1, 146-153.	0.5	3
20	Letter: management of patients with chronic hepatitis C failing repeated courses of interferon-free DAA combination therapy: a translational research perspective with clinical impact. <i>GastroHep</i> , 2019, 1, 154-155.	0.5	1
21	Editorial: simplifying screening for primary liver cancer - do the LCR1 and LCR2 tests hold the key? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 613-614.	3.8	0
22	Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography. <i>Nutrition</i> , 2019, 63-64, 134-140.	2.6	12
23	Identification of an Endoglin Variant Associated With HCV-Related Liver Fibrosis Progression by Next-Generation Sequencing. <i>Frontiers in Genetics</i> , 2019, 10, 1024.	2.4	7
24	The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 393-402.	1.6	14
25	Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection. <i>Journal of Clinical Medicine</i> , 2019, 8, 2101.	2.6	5
26	LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 308-320.	3.8	15
27	Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 80-83.	3.4	8
28	Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. <i>Hepatology</i> , 2019, 69, 760-773.	8.2	176
29	Chronic Hepatitis E in a Heart Transplant Patient: Sofosbuvir and Ribavirin Regimen Not Fully Effective. <i>Antiviral Therapy</i> , 2018, 23, 463-465.	1.1	28
30	Predictive value of liver damage for severe early complications and survival after heart transplantation: A retrospective analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 416-426.	1.6	13
31	Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 569-577.	1.6	16
32	Impact of steatosis and inflammation definitions on the performance of NASH tests. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 384-391.	1.6	15
33	Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1117-1127.	3.8	32
34	Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent study. <i>International Journal of Cardiology</i> , 2018, 266, 100-105.	1.7	6
35	Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis. <i>Gastroenterology</i> , 2017, 152, 2052-2062.e2.	1.4	83
36	Chronic hepatitis E in HIV/HBV coinfecting patient. <i>Aids</i> , 2017, 31, 1346-1348.	2.2	23

#	ARTICLE	IF	CITATIONS
37	Screening studies of transient elastography and FibroTest in the general population. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 246.	8.0	1
38	Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis. <i>Gastroenterology</i> , 2017, 153, 49-52.e5.	1.4	133
39	Cystic Fibrosis-related Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 65, 443-448.	1.7	89
40	Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. <i>PLoS ONE</i> , 2017, 12, e0189436.	2.4	13
41	<i>BRIP1</i> coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease. <i>Oncotarget</i> , 2017, 8, 62842-62857.	1.8	7
42	Rate of employment after liver transplantation in France. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 159-163.	1.6	4
43	A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected patients. <i>Hepatology</i> , 2016, 64, 1462-1472.	8.2	16
44	Fatty liver is an independent predictor of early carotid atherosclerosis. <i>Journal of Hepatology</i> , 2016, 65, 95-102.	4.0	93
45	NAFLD and liver transplantation: Current burden and expected challenges. <i>Journal of Hepatology</i> , 2016, 65, 1245-1257.	4.0	379
46	Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. <i>BMJ Open Gastroenterology</i> , 2016, 3, e000075.	3.1	96
47	Critical comparison of elastography methods to assess chronic liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 402-411.	18.3	208
48	Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1777-1782.	7.9	137
49	Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison. <i>PLoS ONE</i> , 2016, 11, e0163276.	2.4	28
50	Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity. <i>BMJ Open</i> , 2015, 5, e010017.	2.1	10
51	Hepatitis E infection in patients with severe alcoholic hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 1367-1371.	1.6	2
52	Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. <i>European Journal of Internal Medicine</i> , 2015, 26, 30-36.	2.3	44
53	Significant Variations in Elastometry Measurements Made Within Short-term in Patients With Chronic Liver Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 763-771.e6.	4.8	69
54	Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Alcohol-Associated Cirrhosis Awaiting Liver Transplants. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 992-999.e2.	4.8	26

#	ARTICLE	IF	CITATIONS
55	An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: The Liver-FibroSTARD standards. <i>Journal of Hepatology</i> , 2015, 62, 807-815.	4.0	54
56	Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1135-7.	2.4	3
57	Coexistence of circulating HBsAg and anti-HBs antibodies in chronic hepatitis B carriers is not a simple analytical artifact and does not influence HBsAg quantification. <i>Journal of Clinical Virology</i> , 2015, 62, 32-37.	3.4	21
58	Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleeding. <i>Journal of Hepatology</i> , 2015, 62, 816-821.	4.0	29
59	Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis. <i>PLoS ONE</i> , 2015, 10, e0134302.	2.4	15
60	Spleen Stiffness Measurement by Transient Elastography to Diagnose Portal Hypertension in Children. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2014, 59, 197-203.	1.7	46
61	Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest [®]) and transient elastography (FibroScan [®]). <i>Journal of Hepatology</i> , 2014, 60, 706-714.	4.0	101
62	The Interactions of Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases. <i>Clinics in Liver Disease</i> , 2014, 18, 233-248.	2.3	19
63	Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis. <i>Gastroenterology</i> , 2014, 147, 132-142.e4.	1.4	233
64	FibroTest (<sc>FT</sc>) has similar accuracy for cirrhosis in "intention-to-diagnose"™ which is superior to transient elastography (<sc>TE</sc>) in chronic hepatitis B.. <i>Liver International</i> , 2014, 34, 1128-1129.	4.0	0
65	Biopsy as well as FibroTest/Fibrosure Is Suboptimal for Discriminating Intermediate Fibrosis Stages in Patients With Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2014, 109, 1287-1288.	0.4	0
66	Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest [®]) and elastography (FibroScan [®]). <i>Journal of Hepatology</i> , 2014, 61, 994-1003.	4.0	42
67	Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI est fini?" Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 432-439.	1.6	10
68	Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2013, 12, 431-439.	0.6	68
69	Chronic hepatitis C virus (HCV) disease burden and cost in the United States. <i>Hepatology</i> , 2013, 57, 2164-2170.	8.2	402
70	The use of transient elastography and non-invasive serum markers of fibrosis in pediatric liver transplant recipients. <i>Pediatric Transplantation</i> , 2013, 17, 525-534.	1.0	43
71	Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) " NCT01514890. <i>Journal of Hepatology</i> , 2013, 59, 434-441.	4.0	408
72	Liver Stiffness, Platelets, and Spleen Size Is Reliable in Nondecompensated Cirrhotic Patients. <i>Gastroenterology</i> , 2013, 144, 1150.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: A randomized study. <i>Journal of Hepatology</i> , 2013, 58, 452-459.	4.0	7
74	Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up. <i>Journal of Clinical Virology</i> , 2013, 58, 408-414.	3.4	7
75	A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. <i>Journal of Hepatology</i> , 2013, 59, 550-556.	4.0	439
76	Anti-hepatitis C virus antibody detection in oral fluid: Influence of human immunodeficiency virus co-infection. <i>Journal of Clinical Virology</i> , 2013, 58, 385-390.	3.4	10
77	Optimal nonsurgical management of peptic ulcer bleeding, including arterial embolization is associated with a mortality below 1%. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 64-71.	1.6	4
78	Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 675-683.	4.0	138
79	Interferon-γ with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATHRI). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 329-334.	2.9	5
80	Liver fibrosis evaluation using real-time shear wave elastography: Applicability and diagnostic performance using methods without a gold standard. <i>Journal of Hepatology</i> , 2013, 58, 928-935.	4.0	154
81	Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection. <i>Annals of Internal Medicine</i> , 2013, 159, 370.	9.7	2
82	Low 25-hydroxyvitamin D serum levels correlate with the presence of extra-hepatic manifestations in chronic hepatitis C virus infection. <i>Rheumatology</i> , 2012, 51, 2083-2090.	2.1	24
83	M352 THE ESTABLISHMENT OF THE KOREAN HUMAN PAPILLOMAVIRUS COHORT STUDY. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 119, S643.	2.1	0
84	Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis. <i>Liver International</i> , 2012, 32, 852-858.	4.0	75
85	Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfecting patients: A retrospective repeated liver biopsy analysis. <i>Journal of Hepatology</i> , 2012, 56, 49-54.	4.0	18
86	Touching some firm ground in the epidemiology of NASH. <i>Journal of Hepatology</i> , 2012, 56, 23-25.	4.0	16
87	Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: A step toward the truth in the absence of a gold standard. <i>Journal of Hepatology</i> , 2012, 56, 541-548.	4.0	76
88	Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population. <i>Journal of Hepatology</i> , 2012, 57, 541-548.	4.0	65
89	Cost-effectiveness modeling of colorectal cancer: Computed tomography colonography vs colonoscopy or fecal occult blood tests. <i>European Journal of Radiology</i> , 2012, 81, 1413-1419.	2.8	11
90	Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers. <i>BMC Gastroenterology</i> , 2012, 12, 27.	2.0	20

#	ARTICLE	IF	CITATIONS
91	Laboratory Testing for Liver Disease. , 2012, , 201-215.		5
92	Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir. Gastroenterology, 2012, 143, 608-618.e5.	1.4	179
93	Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection. Gastroenterology, 2012, 143, 1244-1252.e12.	1.4	147
94	Gastric mucormycosis: A rare cause of gastrointestinal bleeding in cirrhosis. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, e32-e33.	1.6	3
95	Performances of Elasto-FibroTest® , a combination between FibroTest® and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, 455-463.	1.6	16
96	Liver Biopsy Analysis Has a Low Level of Performance for Diagnosis of Intermediate Stages of Fibrosis. Clinical Gastroenterology and Hepatology, 2012, 10, 657-663.e7.	4.8	101
97	IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology, 2012, 55, 384-394.	8.2	138
98	Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data. PLoS ONE, 2012, 7, e30325.	2.4	121
99	Real Time Identification of Drug-Induced Liver Injury (DILI) through Daily Screening of ALT Results: A Prospective Pilot Cohort Study. PLoS ONE, 2012, 7, e42418.	2.4	19
100	Ranking Hepatologists: Which Hirsch's h-Index to prevent the "œ-crise de foi-e"? Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 375-386.	1.6	22
101	FibroTest® and Fibroscan® performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 720-730.	1.6	26
102	Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C. Gastroenterology, 2011, 140, 1990-1999.	1.4	102
103	FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program. Journal of Hepatology, 2011, 54, 227-235.	4.0	19
104	FibroStic: A large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted. Journal of Hepatology, 2011, 55, 233.	4.0	1
105	Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. Journal of Hepatology, 2011, 55, 756-761.	4.0	91
106	Recombinant activated factor VII in chronic liver diseases: Should we be afraid of thromboembolic events?. Journal of Hepatology, 2011, 55, 483-485.	4.0	9
107	HCV-GenoFibrotest: A combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 204-213.	1.6	24
108	First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy. Journal of Hepatology, 2011, 54, 586-587.	4.0	23

#	ARTICLE	IF	CITATIONS
109	A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. <i>Liver International</i> , 2011, 31, 30-60.	4.0	340
110	What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI). <i>Regulatory Toxicology and Pharmacology</i> , 2011, 60, 290-295.	2.8	32
111	Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B. <i>Current Hepatitis Reports</i> , 2011, 10, 87-97.	0.3	52
112	Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. <i>BMC Gastroenterology</i> , 2011, 11, 39.	2.0	58
113	Performance of the FibroTest cannot be accurately estimated in nine paediatric patients with advanced fibrosis. <i>Scandinavian Journal of Infectious Diseases</i> , 2011, 43, 159-160.	1.5	0
114	The Risk of Multiplying Diagnostic Combinations in the Absence of a Perfect Gold Standard For a Fibrosis Test. <i>American Journal of Gastroenterology</i> , 2011, 106, 1853.	0.4	2
115	High rate of adefovir+lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1290-1296.	1.6	5
116	Biomarkers of Liver Injury for Hepatitis Clinical Trials: A Meta-Analysis of Longitudinal Studies. <i>Antiviral Therapy</i> , 2010, 15, 617-631.	1.1	56
117	Perspectives on Fibrosis Progression in Hepatitis C: An À la Carte Approach to Risk Factors and Staging of Fibrosis. <i>Antiviral Therapy</i> , 2010, 15, 281-291.	1.1	19
118	Assessment of Liver Fibrosis and Steatosis in PBC With FibroScan, MRI, MR-spectroscopy, and Serum Markers. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 58-65.	2.4	87
119	Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. <i>Hepatology</i> , 2010, 51, 445-453.	8.2	317
120	Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). <i>BMC Gastroenterology</i> , 2010, 10, 40.	2.0	175
121	Hirsch Index and Truth Survival in Clinical Research. <i>PLoS ONE</i> , 2010, 5, e12044.	2.4	12
122	Comparison of Elastography, Serum Marker Scores, and Histology for the Assessment of Liver Fibrosis in Hepatitis B Virus (HBV)-Infected Patients in Burkina Faso. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010, 82, 454-458.	1.4	67
123	Factors to Improve the Management of Hepatitis C in Drug Users: An Observational Study in an Addiction Centre. <i>Gastroenterology Research and Practice</i> , 2010, 2010, 1-4.	1.6	27
124	Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression. <i>Gastroenterology</i> , 2010, 138, 513-521.e6.	1.4	803
125	Pentoxifylline Does Not Decrease Short-term Mortality but Does Reduce Complications in Patients With Advanced Cirrhosis. <i>Gastroenterology</i> , 2010, 138, 1755-1762.e2.	1.4	126
126	A comparison of the fibrotic potential of nonalcoholic fatty liver disease and chronic hepatitis C. <i>Human Pathology</i> , 2010, 41, 1178-1185.	2.4	12

#	ARTICLE	IF	CITATIONS
127	Assessment of adrenal function in cirrhotic patients: Salivary cortisol should be preferred. <i>Journal of Hepatology</i> , 2010, 52, 839-845.	4.0	102
128	Evaluation of FibroTest inter-laboratory variations requires standardization on analytical systems and should not be mixed with underpowered histological validation. <i>Clinica Chimica Acta</i> , 2010, 411, 292-293.	1.6	2
129	Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus. <i>Gastroenterology</i> , 2010, 139, 120-129.e18.	1.4	637
130	Interferon λ receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection. <i>Gut</i> , 2010, 59, 1120-1126.	13.9	19
131	Immediate Listing for Liver Transplantation Versus Standard Care for Child-Pugh Stage B Alcoholic Cirrhosis. <i>Annals of Internal Medicine</i> , 2009, 150, 153.	9.7	65
132	The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 18-27.	1.6	11
133	Liver Fibrosis in Viral Hepatitis: Noninvasive Assessment with Acoustic Radiation Force Impulse Imaging versus Transient Elastography. <i>Radiology</i> , 2009, 252, 595-604.	8.5	604
134	Can Nonalcoholic Steatohepatitis be Diagnosed Without Liver Biopsy?. <i>Biomarkers in Medicine</i> , 2009, 3, 353-361.	1.4	7
135	Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. <i>Hepatology</i> , 2009, 49, 97-105.	8.2	247
136	Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. <i>Hepatology</i> , 2009, 49, 436-442.	8.2	132
137	Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. <i>Journal of Medical Virology</i> , 2009, 81, 2029-2035.	5.1	56
138	Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B. <i>Journal of Hepatology</i> , 2009, 51, 11-20.	4.0	185
139	Liver biopsy: The best standard when everything else fails. <i>Journal of Hepatology</i> , 2009, 50, 1267-1268.	4.0	12
140	Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy. <i>Gastroenterology</i> , 2009, 136, 1618-1628.e2.	1.4	225
141	Similarities and Differences Between REPEAT and EPIC3. <i>Annals of Internal Medicine</i> , 2009, 151, 754.	9.7	0
142	Applicability and variability of liver stiffness measurements according to probe position. <i>World Journal of Gastroenterology</i> , 2009, 15, 3398.	3.5	20
143	Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma. <i>Cancer</i> , 2008, 112, 2733-2739.	4.1	135
144	Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency. <i>Hepatology</i> , 2008, 48, 2089-2089.	8.2	94

#	ARTICLE	IF	CITATIONS
145	Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations. <i>Clinical Biochemistry</i> , 2008, 41, 1113-1114.	2.0	5
146	FibroTest-ActiTest as a non-invasive marker of liver fibrosis. <i>Gastroenterologie Clinique Et Biologique</i> , 2008, 32, 22-39.	0.6	104
147	Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 135, 560-567.	2.7	118
148	Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial. <i>Gastroenterology</i> , 2008, 135, 100-110.	1.4	584
149	Nodular regenerative hyperplasia: The main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. <i>Journal of Hepatology</i> , 2008, 48, 74-82.	4.0	162
150	Screening for Liver Fibrosis by Using a Noninvasive Biomarker in Patients With Diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 828-831.	4.8	59
151	Chapter 4 Biomarkers Of Liver Fibrosis. <i>Advances in Clinical Chemistry</i> , 2008, 46, 131-160.	3.4	63
152	Concordance in a World without a Gold Standard: A New Non-Invasive Methodology for Improving Accuracy of Fibrosis Markers. <i>PLoS ONE</i> , 2008, 3, e3857.	2.4	76
153	An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load. <i>PLoS ONE</i> , 2008, 3, e2573.	2.4	64
154	Assessment of liver fibrosis: Noninvasive means. <i>Saudi Journal of Gastroenterology</i> , 2008, 14, 163.	1.2	37
155	Efficacy and Safety of Adefovir Dipivoxil plus Pegylated Interferon- α 2a for the Treatment of Lamivudine-Resistant Hepatitis B virus Infection in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2008, 13, 895-900.	1.1	19
156	Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages. <i>Clinical Chemistry</i> , 2007, 53, 1615-1622.	3.5	228
157	Effect of Prolonged Interferon Therapy on the Outcome of Hepatitis C Virus-Related Cirrhosis: A Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 502-507.	4.8	45
158	FibroMAX [®] : towards a new universal biomarker of liver disease?. <i>Expert Review of Molecular Diagnostics</i> , 2007, 7, 481-490.	3.4	49
159	Association between Leptin, Metabolic Factors and Liver Histology in Patients with Chronic Hepatitis C. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2007, 21, 289-294.	2.0	15
160	High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats. <i>Hepatology</i> , 2007, 46, 1893-1906.	8.2	77
161	Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. <i>Hepatology</i> , 2007, 46, 1872-1882.	8.2	251
162	FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C. <i>Hepatology</i> , 2007, 47, 353-354.	8.2	17

#	ARTICLE	IF	CITATIONS
163	Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC). <i>Cancer</i> , 2007, 109, 1384-1390.	4.1	190
164	Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series. <i>BMC Gastroenterology</i> , 2007, 7, 2.	2.0	47
165	Meta-analyses of FibroTest diagnostic value in chronic liver disease. <i>BMC Gastroenterology</i> , 2007, 7, 40.	2.0	268
166	Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C. <i>Gastroenterologie Clinique Et Biologique</i> , 2007, 31, 815-821.	0.6	5
167	Peut-on traiter la stéatohépatite métabolique ?. <i>Gastroenterologie Clinique Et Biologique</i> , 2007, 31, 333-340.	0.6	1
168	Utilisation des marqueurs non invasifs de fibrose dans la prise en charge de l'hépatite C. <i>Gastroenterologie Clinique Et Biologique</i> , 2007, 31, 34-39.	0.6	3
169	Fibrosis as an End Point for Clinical Trials in Liver Disease: A Report of the International Fibrosis Group. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1214-1220.e1.	4.8	44
170	Intermethod calibration of alanine aminotransferase (ALT) and Î³-glutamyltransferase (GGT) results: application to Fibrotest® and Actitest® scores. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 400-6.	2.4	15
171	Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: A multicenter phase II study with dose adjustment according to baseline serum bilirubin level. <i>European Journal of Cancer</i> , 2006, 42, 456-459.	3.0	62
172	Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. <i>Journal of Hepatology</i> , 2006, 44, 62-67.	4.0	89
173	Natural history and predictors of disease severity in chronic hepatitis C. <i>Journal of Hepatology</i> , 2006, 44, S19-S24.	4.0	445
174	The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. <i>Journal of Hepatology</i> , 2006, 44, 1175-1185.	4.0	50
175	Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholic steato hepatitis in patients with non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2006, 6, 34.	2.0	250
176	Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2006, 6, 6.	2.0	382
177	Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant. <i>Comparative Hepatology</i> , 2006, 5, 1.	0.9	30
178	Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study. <i>Liver International</i> , 2006, 26, 271-278.	4.0	95
179	A novel dendritic cell subset involved in tumor immunosurveillance. <i>Nature Medicine</i> , 2006, 12, 214-219.	30.5	379
180	Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis. <i>Clinical Biochemistry</i> , 2006, 39, 715-721.	2.0	20

#	ARTICLE	IF	CITATIONS
181	Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL). <i>Gastroenterologie Clinique Et Biologique</i> , 2006, 30, 241-246.	0.6	80
182	Diagnostic value of FibroTest with normal serum aminotransferases. <i>Hepatology</i> , 2006, 43, 374-375.	8.2	15
183	Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. <i>Hepatology</i> , 2006, 44, 802-805.	8.2	60
184	Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection. <i>Hepatology</i> , 2006, 44, 1607-1616.	8.2	108
185	Lamivudine and HBV-associated nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 828-829.	0.8	15
186	Laboratory Testing for Liver Disease. , 2006, , 235-250.		0
187	Coexistence of Hepatitis B Surface Antigen (HBs Ag) and Anti-HBs Antibodies in Chronic Hepatitis B Virus Carriers: Influence of Determinant Variants. <i>Journal of Virology</i> , 2006, 80, 2968-2975.	3.4	157
188	Hepatitis C in 6,865 Patients 65 yr or Older: A Severe and Neglected Curable Disease?. <i>American Journal of Gastroenterology</i> , 2006, 101, 1260-1267.	0.4	126
189	A Prospective Analysis of the Prognostic Value of Biomarkers (FibroTest) in Patients with Chronic Hepatitis C. <i>Clinical Chemistry</i> , 2006, 52, 1887-1896.	3.5	211
190	FAS promoter polymorphisms correlate with activity grade in hepatitis C patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 1081-1088.	1.6	19
191	The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. <i>Comparative Hepatology</i> , 2005, 4, 10.	0.9	302
192	Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. <i>The Cochrane Library</i> , 2005, , CD000345.	2.9	15
193	Longitudinal Assessment of Histology Surrogate Markers (FibroTest-ActiTest) During Lamivudine Therapy in Patients with Chronic Hepatitis B Infection. <i>American Journal of Gastroenterology</i> , 2005, 100, 1970-1980.	0.4	128
194	FibroTest-FibroSURE, towards a universal biomarker of liver fibrosis?. <i>Expert Review of Molecular Diagnostics</i> , 2005, 5, 15-21.	3.4	47
195	A reference material for traceability of aspartate aminotransferase (AST) results. <i>Clinical Chemistry and Laboratory Medicine</i> , 2005, 43, 549-53.	2.4	12
196	Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 167-174.	4.8	142
197	A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B. <i>Gastroenterology</i> , 2005, 129, 528-536.	1.4	382
198	NASH: a hidden and silent fibroser finally revealed?. <i>Journal of Hepatology</i> , 2005, 42, 12-14.	4.0	30

#	ARTICLE	IF	CITATIONS
199	Age and gender will survive to competing risks as fibrosis factors. <i>Gastroenterology</i> , 2005, 128, 519-520.	1.4	7
200	Biomarkers as a first-line estimate of injury in chronic liver diseases: Time for a moratorium on liver biopsy?. <i>Gastroenterology</i> , 2005, 128, 1146-1148.	1.4	40
201	Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2005, 128, 1898-1906.	1.4	1,745
202	A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B. <i>Gastroenterology</i> , 2005, 129, 528-536.	1.4	339
203	A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients. <i>Gastroenterology</i> , 2005, 129, 1198-1209.	1.4	248
204	Treatment of Hepatitis C Virus: The First Decade. <i>Seminars in Liver Disease</i> , 2004, 24, 19-24.	3.7	6
205	Long-term outcome improvement in patients with chronic hepatitis D treated with interferon $\hat{\pm}$. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2004, 1, 76-77.	0.9	0
206	Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 323-33.	2.4	102
207	Prospective Analysis of Discordant Results between Biochemical Markers and Biopsy in Patients with Chronic Hepatitis C. <i>Clinical Chemistry</i> , 2004, 50, 1344-1355.	3.5	288
208	Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, .	2.4	53
209	Biomarkers as non-invasive assessment of hepatic fibrosis in chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, S236-S245.	2.9	3
210	Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. <i>Gastroenterologie Clinique Et Biologique</i> , 2004, 28, 554-561.	0.6	72
211	Fat, diabetes, and liver injury in chronic hepatitis C. <i>Current Gastroenterology Reports</i> , 2004, 6, 22-29.	2.5	40
212	Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest). <i>Comparative Hepatology</i> , 2004, 3, 3.	0.9	28
213	Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. <i>Comparative Hepatology</i> , 2004, 3, 8.	0.9	313
214	Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. <i>Arthritis and Rheumatism</i> , 2004, 50, 3668-3678.	7.0	105
215	The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2004, 39, 862-863.	8.2	111
216	The elusiveness of "normal" ALT in fatty liver. <i>Hepatology</i> , 2004, 39, 1172-1172.	8.2	14

#	ARTICLE	IF	CITATIONS
217	Progression of liver fibrosis in women infected with hepatitis C: Long-term benefit of estrogen exposure. <i>Hepatology</i> , 2004, 40, 1426-1433.	8.2	503
218	Treatment of cirrhotic patients in the pegylated interferon era. <i>Digestive and Liver Disease</i> , 2004, 36, S344-S348.	1.0	6
219	Comparing the public health burden of chronic hepatitis C and HIV infection in France. <i>Journal of Hepatology</i> , 2004, 40, 319-326.	4.0	59
220	Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 1367-1373.	1.6	27
221	Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. <i>Aids</i> , 2004, 18, 75-79.	2.2	45
222	The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 386-390.	0.8	20
223	Hepatocellular Carcinoma in NAFLD. , 2004, , 263-275.		0
224	<i>In Vitro</i> Susceptibility of Lamivudine-Resistant Hepatitis B Virus to Adefovir and Tenofovir. <i>Antiviral Therapy</i> , 2004, 9, 353-363.	1.1	101
225	Noninvasive prediction of fibrosis in patients with chronic hepatitis C. <i>Hepatology</i> , 2003, 37, 1220-1221.	8.2	91
226	Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. <i>Hepatology</i> , 2003, 38, 75-85.	8.2	532
227	Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. <i>Hepatology</i> , 2003, 38, 481-492.	8.2	224
228	Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index. <i>Digestive Diseases and Sciences</i> , 2003, 48, 146-153.	2.5	80
229	Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. <i>Cancer</i> , 2003, 98, 2664-2670.	4.1	71
230	Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. <i>Gastroenterology</i> , 2003, 124, A763.	1.4	0
231	A comparison of fibrosis progression in chronic liver diseases. <i>Journal of Hepatology</i> , 2003, 38, 257-265.	4.0	411
232	Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible?. <i>Journal of Hepatology</i> , 2003, 38, 518-520.	4.0	24
233	Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2003, 39, 222-230.	4.0	324
234	Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus. <i>Journal of Hepatology</i> , 2003, 39, 194-199.	4.0	15

#	ARTICLE	IF	CITATIONS
235	Fibrogenic impact of high serum glucose in chronic hepatitis C. <i>Journal of Hepatology</i> , 2003, 39, 1049-1055.	4.0	142
236	Viral hepatitis B. <i>Lancet, The</i> , 2003, 362, 2089-2094.	12.2	933
237	Sarcoidosis and interferon therapy: report of five cases and review of the literature. <i>European Journal of Internal Medicine</i> , 2003, 14, 237-243.	2.3	59
238	Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. <i>Aids</i> , 2003, 17, 721-725.	2.2	177
239	Risk factors for liver fibrosis progression in patients with chronic hepatitis C. <i>Annals of Hepatology</i> , 2003, 2, 5-11.	2.3	61
240	Impact of interferon alpha-2b and of combination with ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. , 2003, , 425-439.		0
241	Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2002, 97, 2419-2425.	0.4	79
242	Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV/HCV International Panel. <i>Aids</i> , 2002, 16, 813-828.	2.2	281
243	Effect of terlipressin (Glypressin®) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study*. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 153-158.	1.6	131
244	Interferon for interferon naive patients with chronic hepatitis C. <i>The Cochrane Library</i> , 2002, , CD000370.	2.9	51
245	Polymorphonuclear neutrophils are a source of hepatocyte growth factor in patients with severe alcoholic hepatitis. <i>Journal of Hepatology</i> , 2002, 36, 342-348.	4.0	59
246	Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. <i>Journal of Hepatology</i> , 2002, 36, 480-487.	4.0	321
247	Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study. <i>Gastroenterology</i> , 2002, 122, 923-930.	1.4	430
248	Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. <i>Gastroenterology</i> , 2002, 122, 1303-1313.	1.4	1,069
249	Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C. <i>Gastroenterology</i> , 2002, 123, 1061-1069.	1.4	923
250	Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. <i>Gastroenterology</i> , 2002, 123, 1494-1499.	1.4	111
251	Discussion on celiac disease in patients with severe liver disease: Gluten-free diet may reverse hepatic failure. <i>Gastroenterology</i> , 2002, 123, 2158-2159.	1.4	11
252	Individual and evidence-based. <i>Lancet, The</i> , 2002, 359, 1514.	12.2	3

#	ARTICLE	IF	CITATIONS
253	Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2002, 36, 812-818.	4.0	98
254	Corrigendum to "Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C" [<i>Hepatol</i> 36 (2002) 812-818]. <i>Journal of Hepatology</i> , 2002, 37, 545.	4.0	0
255	Serum biochemical markers of liver fibrosis in human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-coinfected patients. <i>Journal of Hepatology</i> , 2002, 36, 18.	4.0	1
256	Portal lymphocytic infiltrate in alcoholic liver disease. <i>Human Pathology</i> , 2002, 33, 1170-1174.	2.4	55
257	Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study. <i>Hepatology</i> , 2002, 36, 973-977.	8.2	3
258	A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. <i>Comparative Hepatology</i> , 2002, 1, 3.	0.9	98
259	Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. <i>Hepatology</i> , 2002, 35, 688-693.	8.2	109
260	Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. <i>Hepatology</i> , 2002, 35, 1485-1493.	8.2	415
261	NNRTI-related or -unrelated hepatotoxicity?. <i>Hepatology</i> , 2002, 36, 512-513.	8.2	9
262	Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study. <i>Hepatology</i> , 2002, 36, 973-977.	8.2	163
263	Truth Survival. <i>Annals of Internal Medicine</i> , 2002, 137, 932.	9.7	2
264	Biopsie du foie contre prise de sang pour le suivi de l'hépatite C?. <i>Medecine/Sciences</i> , 2002, 18, 353-356.	0.2	0
265	Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2001, 34, 730-739.	4.0	675
266	Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. <i>Lancet</i> , The, 2001, 357, 1069-1075.	12.2	1,333
267	Early Administration of Vapreotide for Variceal Bleeding in Patients with Cirrhosis. <i>New England Journal of Medicine</i> , 2001, 344, 23-28.	30.7	219
268	Comparison of Bathophenanthroline Sulfonate and Ferene as Chromogens in Colorimetric Measurement of Low Hepatic Iron Concentration. <i>Clinical Chemistry</i> , 2001, 47, 2059-2061.	3.5	36
269	Interferon for acute hepatitis C. <i>The Cochrane Library</i> , 2001, , CD000369.	2.9	24
270	The role of interleukin-10 in severe acute alcoholic hepatitis. <i>Clinical Biochemistry</i> , 2001, 34, 237-238.	2.0	7

#	ARTICLE	IF	CITATIONS
271	Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus coinfecting patients: Impact of protease inhibitor therapy. <i>Hepatology</i> , 2001, 34, 283-287.	8.2	379
272	Successful control of subfulminant hepatitis related to lamivudine-resistant hepatitis B virus in an HIV-infected patient. <i>Aids</i> , 2001, 15, 2463-2464.	2.2	9
273	Is an "1/2 la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?. <i>Hepatology</i> , 2000, 31, 211-218.	8.2	359
274	Natural history of HCV infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2000, 14, 211-228.	2.4	90
275	Impact of Interferon Alfa-2b and Ribavirin on Progression of Liver Fibrosis in Patients With Chronic Hepatitis C. <i>Hepatology</i> , 2000, 32, 1131-1137.	8.2	258
276	Appropriateness of Liver Biopsy. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2000, 14, 543-548.	2.0	158
277	Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis c. <i>American Journal of Gastroenterology</i> , 2000, 95, 1524-1530.	0.4	87
278	Fibrosis in Patients with Chronic Hepatitis C: Detection and Significance. <i>Seminars in Liver Disease</i> , 2000, Volume 20, 0047-0056.	3.7	135
279	Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: A case-control study. <i>Human Pathology</i> , 2000, 31, 69-74.	2.4	71
280	Corticosteroids efficacy in severe alcoholic hepatitis (AH): Retrospective analysis of individual data from the American ANF French randomized controlled trials. <i>Gastroenterology</i> , 2000, 118, A972.	1.4	0
281	The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. <i>Gastroenterology</i> , 2000, 119, 1317-1323.	1.4	174
282	Liver fibrosis in overweight patients. <i>Gastroenterology</i> , 2000, 118, 1117-1123.	1.4	866
283	Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. <i>Journal of Hepatology</i> , 2000, 32, 579-586.	4.0	118
284	Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis c. <i>American Journal of Gastroenterology</i> , 2000, 95, 1524-1530.	0.4	52
285	Summary of the first international symposium on viral hepatitis. <i>Antiviral Research</i> , 1999, 42, 77-96.	4.2	3
286	Impact of hepatitis B and C virus on kidney transplantation outcome. <i>Hepatology</i> , 1999, 29, 257-263.	8.2	521
287	Modeling the hepatitis C virus epidemic in France. <i>Hepatology</i> , 1999, 29, 1596-1601.	8.2	191
288	Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta-analysis. <i>Hepatology</i> , 1999, 29, 1655-1661.	8.2	718

#	ARTICLE	IF	CITATIONS
289	Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfecting patients. <i>Hepatology</i> , 1999, 30, 1054-1058.	8.2	1,217
290	Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. <i>Hepatology</i> , 1999, 30, 1302-1306.	8.2	417
291	Extrahepatic manifestations of chronic hepatitis C. <i>Arthritis and Rheumatism</i> , 1999, 42, 2204-2212.	7.0	566
292	Interferon alfa for chronic hepatitis C infection. <i>Lancet, The</i> , 1999, 353, 500.	12.2	2
293	Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival. <i>Journal of Hepatology</i> , 1999, 30, 1130-1137.	4.0	107
294	Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view. <i>Gastroenterology</i> , 1999, 116, 378-386.	1.4	256
295	EFFECT OF INTERFERON THERAPY ON THE NATURAL HISTORY OF HEPATITIS C VIRUS-RELATED CIRRHOSIS AND HEPATOCELLULAR CARCINOMA. <i>Clinics in Liver Disease</i> , 1999, 3, 869-881.	2.3	43
296	Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 1999, 11, 741.	1.6	144
297	Hepatitis B Virus (HBV) Mutations Associated with Resistance to Lamivudine in Patients Coinfected with HBV and Human Immunodeficiency Virus. <i>Journal of Clinical Microbiology</i> , 1999, 37, 3013-3016.	4.4	69
298	Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. <i>Hepatology</i> , 1998, 27, 868-872.	8.2	287
299	Factors associated with serum alanine transaminase activity in healthy subjects: Consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. <i>Hepatology</i> , 1998, 27, 1213-1219.	8.2	295
300	Hepatitis C: Somber views of natural history and optimistic views of interferon treatment?. <i>Hepatology</i> , 1998, 27, 1443-1444.	8.2	25
301	Trends in primary liver cancer. <i>Lancet, The</i> , 1998, 351, 214-215.	12.2	277
302	Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. <i>Lancet, The</i> , 1998, 351, 1930-1931.	12.2	83
303	Randomised trial of interferon $\hat{\pm}$ 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon $\hat{\pm}$ 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. <i>Lancet, The</i> , 1998, 352, 1426-1432.	12.2	2,270
304	Antibiotic Prophylaxis for the Prevention of Bacterial Infections in Cirrhotic Patients with Ascites: A Meta-Analysis. <i>Digestion</i> , 1998, 59, 54-57.	2.5	40
305	Randomised trial of interferon $\hat{\pm}$ 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon $\hat{\pm}$ 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. <i>European Journal of Gastroenterology and Hepatology</i> , 1998, 10, 1063.	1.6	6
306	Natural history of liver fibrosis progression in patients with chronic hepatitis C. <i>Lancet, The</i> , 1997, 349, 825-832.	12.2	2,848

#	ARTICLE	IF	CITATIONS
307	Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. <i>Journal of Hepatology</i> , 1997, 26, 312-324.	4.0	93
308	Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. <i>Journal of Hepatology</i> , 1996, 25, 135-144.	4.0	428
309	Marked increase in serum CA 19-9 level in patients with alcoholic cirrhosis: report of four cases. <i>European Journal of Gastroenterology and Hepatology</i> , 1996, 8, 1129-1131.	1.6	13
310	Treatment of chronic hepatitis C by interferon for longer duration than six months. <i>Digestive Diseases and Sciences</i> , 1996, 41, 99S-102S.	2.5	16
311	Prevalence of Cholelithiasis According to Alcoholic Liver Disease: A Possible Role of Apolipoproteins AI and AII. <i>Alcoholism: Clinical and Experimental Research</i> , 1995, 19, 75-80.	2.6	22
312	Transforming growth factor- β 1 (TGF- β 1) and TGF- β 1 receptors in normal, cirrhotic, and neoplastic human livers. <i>Hepatology</i> , 1995, 21, 760-766.	8.2	203
313	Hepatitis B and C virus infection in HBsAg-negative alcoholics without i.v. drug abuse or previous blood transfusions. <i>International Hepatology Communications</i> , 1995, 4, 80-87.	0.7	3
314	A Comparison of Three Interferon Alfa-2b Regimens for the Long-Term Treatment of Chronic Non-A, Non-B Hepatitis. <i>New England Journal of Medicine</i> , 1995, 332, 1457-1463.	30.7	452
315	Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. <i>Lancet, The</i> , 1995, 345, 396-397.	12.2	113
316	Acetaldehyde-modified epitopes in liver biopsy specimens of alcoholic and nonalcoholic patients: Localization and association with progression of liver fibrosis. <i>Hepatology</i> , 1994, 19, 367-374.	8.2	73
317	Prednisone-interferon combination in the treatment of chronic hepatitis B: Direct and indirect metanalysis. <i>Hepatology</i> , 1994, 20, 1390-1398.	8.2	61
318	Alpha-2-macroglobulin and hepatic fibrosis. <i>Digestive Diseases and Sciences</i> , 1994, 39, 2426-2432.	2.5	113
319	Evaluation of efficacy of liver transplantation in alcoholic cirrhosis by a case-control study and simulated controls. <i>Lancet, The</i> , 1994, 344, 502-507.	12.2	104
320	No effect of neutralizing antibody to TGF- β 1 in acute CC14-induced liver fibrogenesis. <i>Journal of Hepatology</i> , 1994, 21, 1149-1150.	4.0	3
321	A Two-centre, Randomized, Double-blind Trial of Ornithine Oxoglutarate in 194 Elderly, Ambulatory, Convalescent Subjects. <i>Age and Ageing</i> , 1994, 23, 303-306.	1.7	63
322	Acetaldehyde-modified epitopes in liver biopsy specimens of alcoholic and nonalcoholic patients: Localization and association with progression of liver fibrosis. <i>Hepatology</i> , 1994, 19, 367-374.	8.2	6
323	Laparoscopic treatment without cholecystectomy for gallbladder perforation after liver biopsy. <i>Journal of Hepatology</i> , 1993, 18, 381.	4.0	1
324	Diaphragm Function Is Not Impaired by Pneumoperitoneum After Laparoscopy. <i>Archives of Surgery</i> , 1993, 128, 430.	2.5	19

#	ARTICLE	IF	CITATIONS
325	A Randomized Trial of Prednisolone in Patients with Severe Alcoholic Hepatitis. <i>New England Journal of Medicine</i> , 1992, 326, 507-512.	30.7	380
326	Autoimmune Chronic Hepatitis Exacerbated by Alpha-Interferon. <i>Annals of Internal Medicine</i> , 1992, 116, 51-53.	9.7	147
327	Anti- α -pre-S responses and viral clearance in chronic hepatitis B virus infection. <i>Hepatology</i> , 1992, 15, 26-31.	8.2	24
328	Does elective sclerotherapy improve the efficacy of long-term propranolol for prevention of recurrent bleeding in patients with severe cirrhosis? A prospective multicenter, randomized trial. <i>Hepatology</i> , 1992, 16, 912-919.	8.2	44
329	A Simple Biological Index for Detection of Alcoholic Liver Disease in Drinkers. <i>Gastroenterology</i> , 1991, 100, 1397-1402.	1.4	94
330	A simple biological index for detection of alcoholic liver disease in drinkers. <i>Gastroenterology</i> , 1991, 100, 1397-1402.	1.4	124
331	Portal hypertensive colopathy. <i>Digestive Diseases and Sciences</i> , 1991, 36, 1774-1781.	2.5	101
332	Independent risk factors for hepatocellular carcinoma in french drinkers. <i>Hepatology</i> , 1991, 13, 896-901.	8.2	82
333	Beta-Adrenergic Antagonist Drugs in the Prevention of Gastrointestinal Bleeding in Patients with Cirrhosis and Esophageal Varices. <i>New England Journal of Medicine</i> , 1991, 324, 1532-1538.	30.7	489
334	Diagnostic Value of Serum gamma-Glutamyl-Transferase Activity and Mean Corpuscular Volume in Alcoholic Patients with or without Cirrhosis. <i>Alcoholism: Clinical and Experimental Research</i> , 1990, 14, 250-254.	2.6	23
335	Apolipoproteinemia A and α -fetoprotein in the diagnosis of hepatocellular carcinoma and cirrhosis: Several interpretations. <i>Hepatology</i> , 1990, 11, 892-893.	8.2	0
336	A biphasic pattern of anti-pre-s responses in acute hepatitis B virus infection. <i>Hepatology</i> , 1990, 12, 1271-1277.	8.2	15
337	Serial passage of West-European sporadic non-A non-B hepatitis in rhesus monkeys by inoculation with fecal extracts. <i>Journal of Medical Virology</i> , 1990, 30, 36-41.	5.1	14
338	β -blockers and variceal haemorrhage. <i>Lancet</i> , The, 1990, 336, 506.	12.2	5
339	Expression of histocompatibility antigens and characterization of the lymphocyte infiltrate in hyperplastic polyps of the large bowel. <i>Human Pathology</i> , 1990, 21, 319-324.	2.4	11
340	A Randomised Controlled Study of Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with Cirrhosis. <i>Drugs</i> , 1989, 37, 30-34.	11.2	6
341	Apolipoprotein A1 is a Serum and Tissue Marker of Liver Fibrosis in Alcoholic Patients. <i>Alcoholism: Clinical and Experimental Research</i> , 1989, 13, 829-833.	2.6	25
342	Perisinusoidal cells (Ito cells) enlargement in a family with myotonic dystrophy. <i>Liver</i> , 1989, 9, 276-278.	0.1	5

#	ARTICLE	IF	CITATIONS
343	Prognostic evaluation in cirrhosis. <i>Hepatology</i> , 1988, 8, 982-983.	8.2	0
344	Response to hewitt et al: Retrieval of randomized clinical trials in liver disease. <i>Contemporary Clinical Trials</i> , 1988, 9, 88-90.	2.1	0
345	Detection of hepatitis B surface antigen by a monoclonal radioimmunoassay in the serum of alcoholic patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1988, 3, 153-158.	2.9	0
346	Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. <i>Journal of Hepatology</i> , 1988, 7, 118-125.	4.0	138
347	Failure of haemodynamic measurements to predict recurrent gastrointestinal bleeding in cirrhotic patients receiving propranolol. <i>Journal of Hepatology</i> , 1987, 5, 144-148.	4.0	44
348	Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: A prospective study of factors associated with rebleeding. <i>Hepatology</i> , 1987, 7, 447-451.	8.2	97
349	Relationship between degree of portal hypertension and liver histologic lesions in patients with alcoholic cirrhosis. <i>Digestive Diseases and Sciences</i> , 1987, 32, 337-343.	2.5	45
350	Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. <i>Gastroenterology</i> , 1986, 90, 807-811.	1.4	182
351	A randomized clinical trial of supplementary parenteral nutrition in jaundiced alcoholic cirrhotic patients. <i>Hepatology</i> , 1986, 6, 270-274.	8.2	89
352	Multivariate analysis of prognostic factors in fulminant hepatitis B. <i>Hepatology</i> , 1986, 6, 648-651.	8.2	489
353	Apolipoprotein AI and alcoholic liver disease. <i>Hepatology</i> , 1986, 6, 1391-1395.	8.2	45
354	Propranolol for prevention of recurrent GI bleeding. <i>Hepatology</i> , 1985, 5, 528-528.	8.2	0
355	Relationships between liver histologic lesions and portal hypertension in patients with alcoholic cirrhosis. <i>Hepatology</i> , 1985, 5, 703-705.	8.2	0
356	Prognostic value of serum fibronectin concentration in alcoholic cirrhotic patients. <i>Hepatology</i> , 1985, 5, 819-823.	8.2	32
357	The retrieval of randomized clinical trials in liver disease from the medical literature. <i>Contemporary Clinical Trials</i> , 1985, 6, 271-279.	2.1	153
358	Adrenocorticosteroid administration and peptic ulcer: A critical analysis. <i>Journal of Chronic Diseases</i> , 1985, 38, 457-468.	1.2	55
359	Prognostic Value of Total Serum Bilirubin/ β -Glutamyl Transpeptidase Ratio in Cirrhotic Patients. <i>Hepatology</i> , 1984, 4, 324-327.	8.2	56
360	A Randomized Controlled Study of Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with Cirrhosis: A Final Report. <i>Hepatology</i> , 1984, 4, 355-358.	8.2	293

#	ARTICLE	IF	CITATIONS
361	Relations Between Effectiveness of a Diagnostic Test, Prevalence of the Disease, and Percentages of Uninterpretable Results. <i>Medical Decision Making</i> , 1982, 2, 285-297.	2.7	34
362	The inconvenience of investigations used in hepatology: patients' and hepatologists' opinions. <i>Liver</i> , 1982, 2, 369-375.	0.1	12
363	Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with Cirrhosis. <i>New England Journal of Medicine</i> , 1981, 305, 1371-1374.	30.7	522
364	Infections with Multiple Hepatotropic Viruses. , 0, , 51-73.		3
365	Progression of Fibrosis. , 0, , 511-519.		0